Monocyclic Heteroaryl Cycloalkyldiamine Derivatives

ABSTRACT

The present invention relates to monocyclic heteroaryl cycloalkyldiamine derivatives, to processes for their production, to their use as pharmaceuticals and to pharmaceutical compositions comprising them.

The present invention relates to monocyclic heteroaryl cycloalkyldiaminederivatives, to processes for their production, to their use aspharmaceuticals and to pharmaceutical compositions comprising them.

Spleen tyrosine kinase (SYK), along with ZAP70, has been described to bea member of the SYK-family of tyrosine kinases.

It has been further described that SYK may play a central role in thetransmission of activating signals within B-cells. Consequently theinhibition of SYK appears to be beneficial in the treatment ofautoimmune diseases.

The role of SYK in epithelial malignancies is at present controversial.Several authors have suggested that abnormal Syk function facilitatestransformation in nasopharyngeal carcinoma and head and neck cancerwhile other authors have suggested a tumor suppressor role in breast andgastric cancer.

The compounds of the present invention typically show potentSYK-inhibition, and are therefore potentially useful in the treatment ofa wide range of disorders, for example in the treatment of diseaseand/or disorders associated with the autoimmune system.

The invention therefore provides a compound of the formula (I) or apharmaceutically acceptable salt thereof,

wherein

X1 is CH or N;

Y1, Y2 and Y3 are depending on the position of the double bondindependently of each other CH, NH or N, and the bent bond indicatesaromaticity of the ring system;R1 is H, alkyl, CN, or Hal; andR2 is H, alkyl, or Hal.

As used herein the structural part (L) in a compound of formula (I) is afully aromatic bicyclic system containing at least 1 nitrogen atomrepresented by anyone of the members Y1, Y2 and Y3.

Representative examples for (L) are a 1-indole, 2-indole, 1-indazole,2-indazole, benzimidazole, benztriazole and tautomers thereof.

In another embodiment structural part (L) in a compound of formula (I)is attached to the remaining part of the molecule at the positionindicated by an astrix (*).

In another embodiment the invention provides a compound of formula (I)or a pharmaceutically acceptable salt thereof, wherein

X1 is N; Y1 is NH, Y2 is N and Y3 is CH; or Y1 is CH, Y2 is N and Y3 isNH;

R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (I)or a pharmaceutically acceptable salt thereof, wherein

X1 is N; Y1 is NH; Y2 and Y3 are CH;

R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (II)or a pharmaceutically acceptable salt thereof, wherein

X1 is CH or N;

R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (II)or a pharmaceutically acceptable salt thereof, wherein

X1 is CH;

R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (II)or a pharmaceutically acceptable salt thereof, wherein

X1 is CH;

R1 is H or methyl; andR2 is H or fluoro.

In another embodiment the invention provides a compound of formula (II)or a pharmaceutically acceptable salt thereof, wherein

X1 is N;

R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (II)or a pharmaceutically acceptable salt thereof, wherein

X1 is N;

R1 is H or methyl; andR2 is H or fluoro.

In another embodiment the invention provides a compound of formula (II)or a pharmaceutically acceptable salt thereof, wherein X1 is N, andwherein R1 and R2 are both hydrogen.

In another embodiment the invention provides a compound of formula (III)or a pharmaceutically acceptable salt thereof, wherein

R is H or C₁₋₄alkyl;R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (III)or a pharmaceutically acceptable salt thereof, wherein

R is methyl;R1 is H or methyl; andR2 is H, methyl or fluoro.

In another embodiment the invention provides a compound of formula (IV)or a pharmaceutically acceptable salt thereof, wherein

R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (IV)or a pharmaceutically acceptable salt thereof, wherein

R1 is H or methyl; andR2 is H, methyl or fluoro.

In another embodiment the invention provides a compound of formula (IV)or a pharmaceutically acceptable salt thereof, wherein

R1 is H or methyl; and

R2 is H.

In another embodiment the invention provides a compound of formula (V)or a pharmaceutically acceptable salt thereof,

whereinR is H or C₁₋₄alkyl;R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (V)or a pharmaceutically acceptable salt thereof, wherein

R is H or methyl, in particular methyl; and

R1 and R2 are H.

In another embodiment the invention provides a compound of formula (VI)or a pharmaceutically acceptable salt thereof,

whereinR is H or C₁₋₄alkyl;R1 is H, C₁₋₄alkyl, CN, or Hal; andR2 is H, C₁₋₄alkyl or Hal.

In another embodiment the invention provides a compound of formula (VI)or a pharmaceutically acceptable salt thereof, wherein

R is hydrogen or C₁₋₄alkyl, in particular methyl; andR1 and R2 are both hydrogen.

In another embodiment the invention provides a compound of theinvention, e.g. a compound of formula (I)-(VI) or a pharmaceuticallyacceptable salt thereof, wherein said compound is selected from:

-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(5-fluoro-3-methyl-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-methyl-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indol-4-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1-methyl-1H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(2-methyl-2H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-chloro-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-cyano-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   3-((1R,2S)-2-Amino-cyclohexylamino)-5-(5-fluoro-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylic    acid amide;-   5-((1R,2S)-2-Amino-cyclohexylamino)-3-(1-methyl-1H-indol-4-ylamino)-pyrazine-2-carboxylic    acid amide;-   5-((1R,2S)-2-Amino-cyclohexylamino)-3-(1H-indol-7-ylamino)-pyrazine-2-carboxylic    acid amide; and-   5-((1R,2S)-2-Amino-cyclohexylamino)-3-(3-methyl-1H-indol-7-ylamino)-pyrazine-2-carboxylic    acid amide.

As used herein, the term “alkyl” refers to a fully saturated branched orunbranched hydrocarbon moiety having up to 20 carbon atoms. Unlessotherwise provided, alkyl refers to hydrocarbon moieties having 1 to 16carbon atoms, 1 to 10 carbon atoms, 1 to 7 carbon atoms, or 1 to 4carbon atoms. Representative examples of alkyl include, but are notlimited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl,iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl,3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl,n-octyl, n-nonyl, n-decyl and the like.

As used herein, the term “halogen” or “halo” refers to fluoro, chloro,bromo, and iodo.

As used herein, the term “isomers” refers to different compounds thathave the same molecular formula but differ in arrangement andconfiguration of the atoms. Also as used herein, the term “an opticalisomer” or “a stereoisomer” refers to any of the various stereo isomericconfigurations which may exist for a given compound of the presentinvention and includes geometric isomers. It is understood that asubstituent may be attached at a chiral center of a carbon atom. Theterm “chiral” refers to molecules which have the property ofnon-superimposability on their mirror image partner, while the term“achiral” refers to molecules which are superimposable on their mirrorimage partner. Therefore, the invention includes enantiomers,diastereomers or racemates of the compound. “Enantiomers” are a pair ofstereoisomers that are non-superimposable mirror images of each other. A1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term isused to designate a racemic mixture where appropriate.“Diastereoisomers” are stereoisomers that have at least two asymmetricatoms, but which are not mirror-images of each other. The absolutestereochemistry is specified according to the Cahn-Ingold-Prelog R-Ssystem. When a compound is a pure enantiomer the stereochemistry at eachchiral carbon may be specified by either R or S. Resolved compoundswhose absolute configuration is unknown can be designated (+) or (−)depending on the direction (dextro- or levorotatory) which they rotateplane polarized light at the wavelength of the sodium D line. Certaincompounds described herein contain one or more asymmetric centers oraxes and may thus give rise to enantiomers, diastereomers, and otherstereoisomeric forms that may be defined, in terms of absolutestereochemistry, as (R)- or (S)-.

Depending on the choice of the starting materials and procedures, thecompounds can be present in the form of one of the possible isomers oras mixtures thereof, for example as pure optical isomers, or as isomermixtures, such as racemates and diastereoisomer mixtures, depending onthe number of asymmetric carbon atoms. The present invention is meant toinclude all such possible isomers, including racemic mixtures,diasteriomeric mixtures and optically pure forms. Optically active (R)-and (S)-isomers may be prepared using chiral synthons or chiralreagents, or resolved using conventional techniques. If the compoundcontains a double bond, the substituent may be E or Z configuration. Ifthe compound contains a disubstituted cycloalkyl, the cycloalkylsubstituent may have a cis- or trans-configuration. All tautomeric formsare also intended to be included.

As used herein, the terms “salt” or “salts” refers to an acid additionor base addition salt of a compound of the invention. “Salts” include inparticular “pharmaceutical acceptable salts”. The term “pharmaceuticallyacceptable salts” refers to salts that retain the biologicaleffectiveness and properties of the compounds of this invention and,which typically are not biologically or otherwise undesirable. In manycases, the compounds of the present invention are capable of formingacid and/or base salts by virtue of the presence of amino and/orcarboxyl groups or groups similar thereto.

Pharmaceutically acceptable acid addition salts can be formed withinorganic acids and organic acids, e.g., acetate, aspartate, benzoate,besylate, bromide/hydrobromide, bicarbonate/carbonate,bisulfate/sulfate, camphorsulfonate, chloride/hydrochloride,chlortheophyllonate, citrate, ethandisulfonate, fumarate, gluceptate,gluconate, glucuronate, hippurate, hydroiodide/iodide, isethionate,lactate, lactobionate, laurylsulfate, malate, maleate, malonate,mandelate, mesylate, methylsulphate, naphthoate, napsylate, nicotinate,nitrate, octadecanoate, oleate, oxalate, palmitate, pamoate,phosphate/hydrogen phosphate/dihydrogen phosphate, polygalacturonate,propionate, stearate, succinate, sulfosalicylate, tartrate, tosylate andtrifluoroacetate salts.

In another embodiment the invention relates to any one of the individualcompounds of the invention disclosed and described in the experimentalsection of this application, each forming a pharmaceutically acceptablesalt with each individual acid listed above.

Inorganic acids from which salts can be derived include, for example,hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid,phosphoric acid, and the like.

Organic acids from which salts can be derived include, for example,acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid,malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid,benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid,toluenesulfonic acid, sulfosalicylic acid, and the like.Pharmaceutically acceptable base addition salts can be formed withinorganic and organic bases.

In another embodiment the invention relates to any one of the individualcompounds of the invention disclosed and described in the experimentalsection of this application, each forming a pharmaceutically acceptablesalt with each individual acid listed above.

Inorganic bases from which salts can be derived include, for example,ammonium salts and metals from columns I to XII of the periodic table.In certain embodiments, the salts are derived from sodium, potassium,ammonium, calcium, magnesium, iron, silver, zinc, and copper;particularly suitable salts include ammonium, potassium, sodium, calciumand magnesium salts.

Organic bases from which salts can be derived include, for example,primary, secondary, and tertiary amines, substituted amines includingnaturally occurring substituted amines, cyclic amines, basic ionexchange resins, and the like. Certain organic amines includeisopropylamine, benzathine, cholinate, diethanolamine, diethylamine,lysine, meglumine, piperazine and tromethamine.

The pharmaceutically acceptable salts of the present invention can besynthesized from a basic or acidic moiety, by conventional chemicalmethods. Generally, such salts can be prepared by reacting free acidforms of these compounds with a stoichiometric amount of the appropriatebase (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or thelike), or by reacting free base forms of these compounds with astoichiometric amount of the appropriate acid. Such reactions aretypically carried out in water or in an organic solvent, or in a mixtureof the two. Generally, use of non-aqueous media like ether, ethylacetate, ethanol, isopropanol, or acetonitrile is desirable, wherepracticable. Lists of additional suitable salts can be found, e.g., in“Remington's Pharmaceutical Sciences”, 20th ed., Mack PublishingCompany, Easton, Pa., (1985); and in “Handbook of Pharmaceutical Salts:Properties, Selection, and Use” by Stahl and Wermuth (Wiley-VCH,Weinheim, Germany, 2002).

Any formula given herein is also intended to represent unlabeled formsas well as isotopically labeled forms of the compounds. Isotopicallylabeled compounds have structures depicted by the formulas given hereinexcept that one or more atoms are replaced by an atom having a selectedatomic mass or mass number. Examples of isotopes that can beincorporated into compounds of the invention include isotopes ofhydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine,such as ²H, ³H, ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸F ³¹P, ³²P, ³⁵S, ³⁶Cl, ¹²⁵Irespectively. The invention includes various isotopically labeledcompounds as defined herein, for example those into which radioactiveisotopes, such as ³H and ¹⁴C, or those into which non-radioactiveisotopes, such as ²H and ¹³C are present. Such isotopically labelledcompounds are useful in metabolic studies (with ¹⁴C), reaction kineticstudies (with, for example ²H or ³H), detection or imaging techniques,such as positron emission tomography (PET) or single-photon emissioncomputed tomography (SPECT) including drug or substrate tissuedistribution assays, or in radioactive treatment of patients. Inparticular, an ¹⁸F or labeled compound may be particularly desirable forPET or SPECT studies. Isotopically-labeled compounds of the inventioncan generally be prepared by conventional techniques known to thoseskilled in the art or by processes analogous to those described in theaccompanying Examples and Preparations using an appropriateisotopically-labeled reagents in place of the non-labeled reagentpreviously employed.

Further, substitution with heavier isotopes, particularly deuterium(i.e., ²H or D) may afford certain therapeutic advantages resulting fromgreater metabolic stability, for example increased in vivo half-life orreduced dosage requirements or an improvement in therapeutic index. Itis understood that deuterium in this context is regarded as asubstituent of a compound of the invention. The concentration of such aheavier isotope, specifically deuterium, may be defined by the isotopicenrichment factor. The term “isotopic enrichment factor” as used hereinmeans the ratio between the isotopic abundance and the natural abundanceof a specified isotope. If a substituent in a compound of this inventionis denoted deuterium, such compound has an isotopic enrichment factorfor each designated deuterium atom of at least 3500 (52.5% deuteriumincorporation at each designated deuterium atom), at least 4000 (60%deuterium incorporation), at least 4500 (67.5% deuterium incorporation),at least 5000 (75% deuterium incorporation), at least 5500 (82.5%deuterium incorporation), at least 6000 (90% deuterium incorporation),at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97%deuterium incorporation), at least 6600 (99% deuterium incorporation),or at least 6633.3 (99.5% deuterium incorporation).

Pharmaceutically acceptable solvates in accordance with the inventioninclude those wherein the solvent of crystallization may be isotopicallysubstituted, e.g. D₂O, d₆-acetone, d₆-DMSO.

Compounds of the invention, e.g. compounds of formula (I) that containgroups capable of acting as donors and/or acceptors for hydrogen bondsmay be capable of forming co-crystals with suitable co-crystal formers.These co-crystals may be prepared from compounds of the invention byknown co-crystal forming procedures. Such procedures include grinding,heating, co-subliming, co-melting, or contacting in solution compoundsof the invention with the co-crystal former under crystallizationconditions and isolating co-crystals thereby formed. Suitable co-crystalformers include those described in WO 2004/078163. Hence the inventionfurther provides co-crystals comprising a compound of the invention.

As used herein, the term “pharmaceutically acceptable carrier” includesany and all solvents, dispersion media, coatings, surfactants,antioxidants, preservatives (e.g., antibacterial agents, antifungalagents), isotonic agents, absorption delaying agents, salts,preservatives, drug stabilizers, binders, excipients, disintegrationagents, lubricants, sweetening agents, flavoring agents, dyes, and thelike and combinations thereof, as would be known to those skilled in theart (see, for example, Remington's Pharmaceutical Sciences, 18th Ed.Mack Printing Company, 1990, pp. 1289-1329). Except insofar as anyconventional carrier is incompatible with the active ingredient, its usein the therapeutic or pharmaceutical compositions is contemplated.

The term “a therapeutically effective amount” of a compound of thepresent invention refers to an amount of the compound of the presentinvention that will elicit the biological or medical response of asubject, for example, reduction or inhibition of an enzyme or a proteinactivity, or ameliorate symptoms, alleviate conditions, slow or delaydisease progression, or prevent a disease, etc. In one non-limitingembodiment, the term “a therapeutically effective amount” refers to theamount of the compound of the present invention that, when administeredto a subject, is effective to (1) at least partially alleviating,inhibiting, preventing and/or ameliorating a condition, or a disorder ora disease (i) mediated by SYK, or (ii) associated with SYK activity, or(iii) characterized by activity (normal or abnormal) of SYK; or (2)reducing or inhibiting the activity of SYK; or (3) reducing orinhibiting the expression of SYK. In another non-limiting embodiment,the term “a therapeutically effective amount” refers to the amount ofthe compound of the present invention that, when administered to a cell,or a tissue, or a non-cellular biological material, or a medium, iseffective to at least partially reducing or inhibiting the activity ofSYK; or at least partially reducing or inhibiting the expression of SYK.

The term “subject” as used herein may refer to an animal. The animal maybe a mammal. A subject also refers to for example, primates (e.g.,humans, male or female), cows, sheep, goats, horses, dogs, cats,rabbits, rats, mice, fish, birds and the like. In certain embodiments,the subject is a primate. In yet other embodiments, the subject is ahuman.

As used herein, the term “inhibit”, “inhibition” or “inhibiting” refersto the reduction or suppression of a given condition, symptom, ordisorder, or disease, or a significant decrease in the baseline activityof a biological activity or process.

As used herein, the term “treat”, “treating” or “treatment” of anydisease or disorder refers in one embodiment, to ameliorating thedisease or disorder (i.e., slowing or arresting or reducing thedevelopment of the disease or at least one of the clinical symptomsthereof). In another embodiment “treat”, “treating” or “treatment”refers to alleviating or ameliorating at least one physical parameterincluding those which may not be discernible by the patient. In yetanother embodiment, “treat”, “treating” or “treatment” refers tomodulating the disease or disorder, either physically, (e.g.,stabilization of a discernible symptom), physiologically, (e.g.,stabilization of a physical parameter), or both. In yet anotherembodiment, “treat”, “treating” or “treatment” refers to preventing ordelaying the onset or development or progression of the disease ordisorder.

As used herein, a subject is “in need of” a treatment if such subjectwould benefit biologically, medically or in quality of life from suchtreatment.

As used herein, the term “a,” “an,” “the” and similar terms used in thecontext of the present invention (especially in the context of theclaims) are to be construed to cover both the singular and plural unlessotherwise indicated herein or clearly contradicted by the context.

All methods described herein can be performed in any suitable orderunless otherwise indicated herein or otherwise clearly contradicted bycontext. The use of any and all examples, or exemplary language (e.g.“such as”) provided herein is intended merely to better illuminate theinvention and does not pose a limitation on the scope of the inventionotherwise claimed.

Any asymmetric atom (e.g., carbon or the like) of the compound(s) of thepresent invention can be present in racemic or enantiomericallyenriched, for example the (R)-, (S)- or (R,S)-configuration. In certainembodiments, each asymmetric atom has at least 50% enantiomeric excess,at least 60 enantiomeric excess, at least 70% enantiomeric excess, atleast 80% enantiomeric excess, at least 90% enantiomeric excess, atleast 95% enantiomeric excess, or at least 99% enantiomeric excess inthe (R)- or (S)-configuration. Substituents at atoms with unsaturateddouble bonds may, if possible, be present in cis- (Z)- or trans-(E)-form.

Accordingly, as used herein a compound of the present invention can bein the form of one of the possible isomers, rotamers, atropisomers,tautomers or mixtures thereof, for example, as substantially puregeometric (cis or trans) isomers, diastereomers, optical isomers(antipodes), racemates or mixtures thereof.

Any resulting mixtures of isomers can be separated on the basis of thephysicochemical differences of the constituents, into the pure orsubstantially pure geometric or optical isomers, diastereomers,racemates, for example, by chromatography and/or fractionalcrystallization.

Any resulting racemates of final products or intermediates can beresolved into the optical antipodes by known methods, e.g., byseparation of the diastereomeric salts thereof, obtained with anoptically active acid or base, and liberating the optically activeacidic or basic compound. In particular, a basic moiety may thus beemployed to resolve the compounds of the present invention into theiroptical antipodes, e.g., by fractional crystallization of a salt formedwith an optically active acid, e.g., tartaric acid, dibenzoyl tartaricacid, diacetyl tartaric acid, di-O,O′-p-toluoyl tartaric acid, mandelicacid, malic acid or camphor-10-sulfonic acid. Racemic products can alsobe resolved by chiral chromatography, e.g., high pressure liquidchromatography (HPLC) using a chiral adsorbent.

Furthermore, the compounds of the present invention, including theirsalts, can also be obtained in the form of their hydrates, or includeother solvents used for their crystallization. The compounds of thepresent invention may inherently or by design form solvates withpharmaceutically acceptable solvents (including water); therefore, it isintended that the invention embrace both solvated and unsolvated forms.The term “solvate” refers to a molecular complex of a compound of thepresent invention (including pharmaceutically acceptable salts thereof)with one or more solvent molecules. Such solvent molecules are thosecommonly used in the pharmaceutical art, which are known to be innocuousto the recipient, e.g., water, ethanol, and the like. The term “hydrate”refers to the complex where the solvent molecule is water.

The compounds of the present invention, including salts, hydrates andsolvates thereof, may inherently or by design form polymorphs.

In another aspect, the present invention provides a pharmaceuticalcomposition comprising a compound of the present invention and apharmaceutically acceptable carrier. The pharmaceutical composition canbe formulated for particular routes of administration such as oraladministration, parenteral administration, and rectal administration,etc. In addition, the pharmaceutical compositions of the presentinvention can be made up in a solid form (including without limitationcapsules, tablets, pills, granules, powders or suppositories), or in aliquid form (including without limitation solutions, suspensions oremulsions). The pharmaceutical compositions can be subjected toconventional pharmaceutical operations such as sterilization and/or cancontain conventional inert diluents, lubricating agents, or bufferingagents, as well as adjuvants, such as preservatives, stabilizers,wetting agents, emulsifers and buffers, etc. Typically, thepharmaceutical compositions are tablets or gelatin capsules comprisingthe active ingredient together with

-   -   a) diluents, e.g., lactose, dextrose, sucrose, mannitol,        sorbitol, cellulose and/or glycine;    -   b) lubricants, e.g., silica, talcum, stearic acid, its magnesium        or calcium salt and/or polyethyleneglycol; for tablets also    -   c) binders, e.g., magnesium aluminum silicate, starch paste,        gelatin, tragacanth, methylcellulose, sodium        carboxymethylcellulose and/or polyvinylpyrrolidone; if desired    -   d) disintegrants, e.g., starches, agar, alginic acid or its        sodium salt, or effervescent mixtures; and/or    -   e) absorbents, colorants, flavors and sweeteners.

Tablets may be either film coated or enteric coated according to methodsknown in the art.

Suitable compositions for oral administration include an effectiveamount of a compound of the invention in the form of tablets, lozenges,aqueous or oily suspensions, dispersible powders or granules, emulsion,hard or soft capsules, or syrups or elixirs. Compositions intended fororal use are prepared according to any method known in the art for themanufacture of pharmaceutical compositions and such compositions cancontain one or more agents selected from the group consisting ofsweetening agents, flavoring agents, coloring agents and preservingagents in order to provide pharmaceutically elegant and palatablepreparations. Tablets may contain the active ingredient in admixturewith nontoxic pharmaceutically acceptable excipients which are suitablefor the manufacture of tablets. These excipients are, for example, inertdiluents, such as calcium carbonate, sodium carbonate, lactose, calciumphosphate or sodium phosphate; granulating and disintegrating agents,for example, corn starch, or alginic acid; binding agents, for example,starch, gelatin or acacia; and lubricating agents, for example magnesiumstearate, stearic acid or talc. The tablets are uncoated or coated byknown techniques to delay disintegration and absorption in thegastrointestinal tract and thereby provide a sustained action over alonger period. For example, a time delay material such as glycerylmonostearate or glyceryl distearate can be employed. Formulations fororal use can be presented as hard gelatin capsules wherein the activeingredient is mixed with an inert solid diluent, for example, calciumcarbonate, calcium phosphate or kaolin, or as soft gelatin capsuleswherein the active ingredient is mixed with water or an oil medium, forexample, peanut oil, liquid paraffin or olive oil.

Certain injectable compositions are aqueous isotonic solutions orsuspensions, and suppositories are advantageously prepared from fattyemulsions or suspensions. Said compositions may be sterilized and/orcontain adjuvants, such as preserving, stabilizing, wetting oremulsifying agents, solution promoters, salts for regulating the osmoticpressure and/or buffers. In addition, they may also contain othertherapeutically valuable substances. Said compositions are preparedaccording to conventional mixing, granulating or coating methods,respectively, and contain about 0.1-75%, or contain about 1-50%, of theactive ingredient.

Suitable compositions for transdermal application include an effectiveamount of a compound of the invention with a suitable carrier. Carrierssuitable for transdermal delivery include absorbable pharmacologicallyacceptable solvents to assist passage through the skin of the host. Forexample, transdermal devices are in the form of a bandage comprising abacking member, a reservoir containing the compound optionally withcarriers, optionally a rate controlling barrier to deliver the compoundof the skin of the host at a controlled and predetermined rate over aprolonged period of time, and means to secure the device to the skin.

Suitable compositions for topical application, e.g., to the skin andeyes, include aqueous solutions, suspensions, ointments, creams, gels orsprayable formulations, e.g., for delivery by aerosol or the like. Suchtopical delivery systems will in particular be appropriate for dermalapplication, e.g., for the treatment of skin cancer, e.g., forprophylactic use in sun creams, lotions, sprays and the like. They arethus particularly suited for use in topical, including cosmetic,formulations well-known in the art. Such may contain solubilizers,stabilizers, tonicity enhancing agents, buffers and preservatives.

As used herein a topical application may also pertain to an inhalationor to an intranasal application. They may be conveniently delivered inthe form of a dry powder (either alone, as a mixture, for example a dryblend with lactose, or a mixed component particle, for example withphospholipids) from a dry powder inhaler or an aerosol spraypresentation from a pressurised container, pump, spray, atomizer ornebuliser, with or without the use of a suitable propellant.

The present invention further provides anhydrous pharmaceuticalcompositions and dosage forms comprising the compounds of the presentinvention as active ingredients, since water may facilitate thedegradation of certain compounds.

Anhydrous pharmaceutical compositions and dosage forms of the inventioncan be prepared using anhydrous or low moisture containing ingredientsand low moisture or low humidity conditions. An anhydrous pharmaceuticalcomposition may be prepared and stored such that its anhydrous nature ismaintained. Accordingly, anhydrous compositions are packaged usingmaterials known to prevent exposure to water such that they can beincluded in suitable formulary kits. Examples of suitable packaginginclude, but are not limited to, hermetically sealed foils, plastics,unit dose containers (e.g., vials), blister packs, and strip packs.

The invention further provides pharmaceutical compositions and dosageforms that comprise one or more agents that reduce the rate by which thecompound of the present invention as an active ingredient willdecompose. Such agents, which are referred to herein as “stabilizers,”include, but are not limited to, antioxidants such as ascorbic acid, pHbuffers, or salt buffers, etc.

Methods of Synthesizing

Agents of the invention, for example compounds in accordance to thedefinition of formula (I), (II), (Ill), (IV), (V) or (VI) may beprepared by a reaction sequence provided infra or explicitly shown inthe reaction schemes of the experimental part (see hereinbelow).

In another embodiment the invention relates to a process ofmanufacturing a compound of formula (I) or a pharmaceutically acceptablesalt thereof,

wherein

X1 is N;

Y1, Y2 and Y3 are depending on the position of the double bond CH, NH orN, and the bent bond indicates aromaticity of the ring system;R1 is H, alkyl, CN, or Hal; andR2 is H, alkyl, or Hal;wherein in accordance to the scheme shown below,a carboxylic acid derivative (1), wherein Alk is alkyl and typically isethyl, is reacted with an amino-derivative (2) in the presence orabsence of a solvent, e.g. in the presence of an aprotic solvent such asNMP, to yield intermediate (3), wherein if a free amino group is presentsaid amino group is then protected in an optional protecting step, e.g.by reacting intermediate (3) e.g. with an agent yielding a protectivegroup such as BOC₂O typically in the presence of a base such as DMAP anda solvent such as THF to yield the protected intermediate (4), which isreacted with ammonia typically in the presence of a solvent such asmethanol, or ethanol or a mixture thereof to yield the carboxylic acidamide (5), which amide (5) is first activated, e.g. by reacting with anorganic peroxyacid such as perbenzoic acid or MCPBA and is then reactedwith cyclohexanediamine-derivative (6) typically in the presence of abase such as triethylamine and a solvent such as DMF to yield theprotected derivative (7), which is reacted with an acid to remove theprotecting groups, such as TFA or HCl typically in the presence of asolvent such as dichloromethane or methanol to yield a compound offormula (I), or alternatively the protected derivative (7) is reacted ata low temperature with an acid, e.g. HCl to remove one protecting groupand thereafter is reacted with a base, e.g. NaOCH₃ to remove the secondprotecting group to yield a compound of formula (I),

which may optionally be reacted with an appropriate acid to yield asalt, e.g. a pharmaceutically acceptable salt.

In another embodiment the invention relates to a process ofmanufacturing a compound of formula (I) or a pharmaceutically acceptablesalt thereof,

wherein

X1 is CH;

Y1, Y2 and Y3 are depending on the position of the double bond CH, NH orN, and the bent bond indicates aromaticity of the ring system;R1 is H, alkyl, CN, or Hal; andR2 is H, alkyl, or Hal;wherein in accordance to the scheme shown below,a carboxylic acid derivative (12), wherein Alk is alkyl and typically isethyl, is reacted with cyclohexanediamine-derivative (6) typically inthe presence of a base such as triethylamine and a solvent such as DMFto yield a derivative (13), which is reacted with intermediate (2) inthe presence of a solvent such as dioxane, a base such as K₂CO₃, apaladium salt such as Pd(OAc)₂ and a ligand such as Xantphos to yield anintermediate (15), which is reacted with a metal hydroxide such as LiOHin the presence of solvents such as dioxane and water to yield acarboxylic acid (16), which is activated with an amide coupling reagentsuch as COMU in the presence of a base such as DIPEA and a solvent suchas DMF and subsequently reacted with NH₃ to yield an amide (17), whichis reacted with an acid such as HCl to remove the protecting group toyield a compound of formula (I),

which may optionally be reacted with an appropriate acid to yield asalt, e.g. a pharmaceutically acceptable salt.

In another embodiment the invention relates to a process ofmanufacturing a compound of formula (I) or a pharmaceutically acceptablesalt thereof,

wherein

X1 is CH;

Y1, Y2 and Y3 are depending on the position of the double bond CH, NH orN, and the bent bond indicates aromaticity of the ring system;R1 is H, alkyl, CN, or Hal; andR2 is H, alkyl, or Hal;wherein in accordance to the scheme shown below,a nitrile derivative (18) is reacted with cyclohexanediamine-derivative(6) typically in the presence of a base such as triethylamine and asolvent such as DMF to yield a derivative (19), which is reacted with anamino-derivative (2) in the presence of a solvent such as dioxane, abase such as K₂CO₃, a paladium salt such as Pd(OAc)₂ and a ligand suchas Xantphos to yield an intermediate (20), which is reacted with ametalhydroxide such as NaOH and H₂O₂ in the presence of solvents such asDMSO and EtOH to yield an amide (21) which is which is reacted with anacid such as HCl to remove the protecting group to yield a compound offormula (I),

which may optionally be reacted with an appropriate acid to yield asalt, e.g. a pharmaceutically acceptable salt.

Experimental Section 1. Analytical Methods Liquid Chromatography:UPLC/MS: Waters Acquity UPLC+Waters ZQ2000 MS UV-PDA: 210-450 nM

MS range: 100-1200 Da

Column: Acquity HSS T3 2.1×50 mm 1.8μ at 60° C.

Mobile phase: A: water+0.05% formic acid

-   -   B: acetonitrile+0.04% formic acid

Time [minutes] Flow [ml/min] A [%] B [%] 0.00 1.000 95 5 1.40 1.000 2 981.80 1.000 2 98 1.90 1.000 95 5 2.00 1.000 95 5

2. Preparative HPLC Column: Waters SunFire 30×100 mm, C18, 5 μm

Flow: 20 ml/minSolvent: Acetonitril/water/0.1% TFA (gradient)

Abbreviations:

Boc2O: Di-t-butyl dicarbonateCOMU:(1-Cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbeniumhexafluorophosphate

DIPEA: N,N-Diisopropylethylamine DMAP: 4-Dimethylaminopyridine DMF:Dimethylformamide DMSO: Dimethylsolfoxide HPLC: High Pressure LiquidChromatography

MCPBA: meta-Chloroperoxybenzoic acidNMP: N-Methyl-2-pyrrolidonTFA: Trifluoroacetic acid

THF: Tetrahydrofuran UPLC: Ultra Performance Liquid Chromatography

Xantphos: 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene

To the extent compounds are mentioned as such in a reaction schemeand/or within the full experimental part, such a compound is eithercommerically available or if not, has been fully described in the priorart, and hence can be obtained accordingly for carrying out acorresponding reaction step.

EXAMPLE 1.13-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

Step 1: The indole-compound 2 (283 mg) was added to a solution of 1 (500mg) in NMP (2 mL) and the mixture stirred at 25° C. for 15 min. Themixture was added to water, the precipitate collected and dried to givecompound 3 (660 mg) as a beige solid. UPLC/MS found for C15H15N5O2S as(M+H)⁺ 329.9; UPLC retention time 1.07 min.

Step 2: To a suspension of 3 (660 mg) and DMAP (22.5 mg) in THF (4 mL)was added at 0° C. a solution of (Boc)₂O in THF (3 mL). The mixture wasstirred at 25° C. for 30 min. The solvent was removed and the residuepurified by chromatography on silica (gradient cyclohexane/ethylacetate) to give compound 4 (555 mg) as a yellow solid. UPLC/MS foundfor C20H23N5O4S as (M+H)⁺ 430.0; UPLC retention time 1.28 min.

Step 3: A mixture of 4 (260 mg) and NH₃ (2 mL of a 7 molar solution inmethanol) was stirred at 25° C. for 45 min. The mixture was added to icewater, the precipitate collected and dried to give compound 5 (183 mg).UPLC/MS found for C18H20N6O3S as (M+H)⁺ 401.0; UPLC retention time 1.09min.

Step 4: To a solution of 5 (180 mg) in DMF (2 mL) was added MCPBA (199mg) at 0° C. and the mixture stirred for 45 min. NEt₃ (0.31 mL) and 6(95 mg) were added and the mixture stirred at 65° C. for 15 min. Thesolvent was removed and the residue purified by HPLC to give compound 7(222 mg) as a yellow solid. UPLC/MS found for C28H38N8O5 as (M+H)⁺567.2; UPLC retention time 1.13 min.

Step 5: A solution of 7 (222 mg) in CH₂Cl₂ (2 mL), TFA (2 mL) and water(0.02 mL) was stirred at 25° C. for 0.5 h. Then the mixture was kept for16 h at 0° C. and for 1 h at 25° C. The solvents were evaporated and theresidue purified by HPLC. Product was dissolved in CH₂Cl₂ and extractedwith aqueous NaOH to give Example 1.1 (62 mg) as a yellow solid. ¹H-NMR(400 MHz; CD3OD, 25° C.): 7.52 (1H, d); 7.23 (1H, d); 7.16 (1H, d); 7.04(1H, t); 6.51 (1H, d); 3.58 (1H, m); 2.82 (1H, m); 1.75-1.15 (8H, m);UPLC/MS found for C18H22N8O as (M+H)⁺ 367.1; UPLC retention time 0.64min.

Alternative Step 5:

Step 5.1: To a solution of compound 7 (4.56 g) in a mixture of CH₂Cl₂(400 ml) and MeOH (40 ml) was added dropwise a solution of HCl in dioxan(40.2 ml, 4 N) at 0° C. and the mixture stirred for 16 h at 25° C. Themixture was diluted with CH₂Cl₂ and washed with bicarbonate solution.The aqueous solution was extracted with CH₂Cl₂ and the combined organicphases washed with brine. The organic phase was passed through aphase-separating column containing a short bed of Na₂SO₄ and the solvendremoved to give a yellow solid, i.e. compound 7a which was used withoutfurther purification in the next step. UPLC/MS found for C18H22N8O as(M+H)⁺ 467.1; UPLC retention time 0.77 min.

Step 5.2: To a solution of compound 7a (3.48 g) in a mixture of THF (120ml) and MeOH (50 ml) was added within 15 min a solution of NaOMe in MeOH(8.29 ml, 5.4 N) at 25° C. and the mixture stirred for 3 h. The mixturewas diluted with ethyl acetate and washed with water. The aqueoussolution was extracted with ethyl acetate and the combined organicphases washed with bicarbonate solution followed by brine. The organicphase was passed through a phase-separating column and the solvendremoved to give a yellow solid. The crude material was purified using aBiotage KP-NH column (0-10% MeOH in ethyl acetate) to give Example 1.1.(1.90 g) as a yellow solid. ¹H-NMR, and UPLC/MS see data provided understep 5.

Accordingly, in another embodiment the invention relates to a process ofmanufacturing a compound of formula (II), as shown in the scheme below,wherein X1 is N and the additional variables are as definedhereinbefore, e.g. as in claim 1, and wherein Alk stands for alkyl asdefined hereinbefore, especially C1-C4alkyl, wherein a carboxylic acidderivative (1), wherein Alk typically is ethyl, is reacted with a7-amino-indole derivative (2) to yield indole intermediate (3) the freeamino group of which is then protected in a protecting step, e.g. byreacting indole-derivative (3) e.g. with a protecting agent such asBOC₂O typically in the presence of a base such as DMAP and a solventsuch as THF to yield the protected indole (4), which is reacted withammonia typically in the presence of a solvent such as methanol, orethanol or a mixture thereof to yield the carboxylic acid amide (5),which amide (5) is first activated, e.g. by reacting with an organicperoxyacid such as perbenzoic acid or MCPBA and is then reacted withcyclohexanediamine-derivative (6) typically in the presence of a basesuch as triethylamine and a solvent such as DMF to yield the protectedderivative (7), which is reacted with an acid to remove the protectinggroups, such as TFA or HCl typically in the presence of a solvent suchas dichloromethane or methanol to yield a compound of formula (II), oralternatively the protected derivative (7) is first reacted with anacid, typically HCl, generally in the presence of a solvent, e.g.dioxin, THF, or ethanol or the like and typically at a temperature belowroom temperature, typically at 0° C. to yield an intermediate carryingonly one protecting group, which intermediate is then reacted with abase, e.g. NaOMe generally in the presence of a solvent, e.g. methanolto yield the final compound of formula (II), which may be optionallyreacted with an appropriate acid to furnish a salt, especially apharmaceutically acceptable salt.

Examples 1.2; 1.3 &1.4 were prepared following procedures similar tothose described for Example 1.1. The only deviating reaction partner inthe above reaction scheme were the differently substitutedindole-compounds listed in the above scheme as compound 2.

EXAMPLE 1.23-((1R,2S)-2-Amino-cyclohexylamino)-5-(5-fluoro-3-methyl-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

This compound was obtained by taking in reaction step 2 the reactionpartner 3-methyl-5-fluoro-7-amino-indole. Upon purification via HPLC thecompound had been characterized:

¹H-NMR (400 MHz; CD₃OD, 25° C.): 7.27 (1H, m); 7.10 (2H, m), 3.70 (1H,m); 3.00 (1H, m); 2.30 (3H, s); 1.70-1.25 (8H, m); UPLC/MS found forC19H23FN8O as (M+H)⁺ 399.1; UPLC retention time 0.69 min.

Preparation of 3-methyl-5-fluoro-7-amino-indole

A mixture of 7-Bromo-5-fluoro-3-methyl-indole (2.5 g), Cu (0.77 g), CuBr(1.57 g) and NH₃ (30 mL of a 33% aqueous solution) was heated in anautoclave for 2 h at 170° C. The mixture was diluted with water andextracted with ethyl acetate. The organic phase was dried and thesolvent removed to give 3-methyl-5-fluoro-7-amino-indole (1.84 g) as anoil which was used without further purification. UPLC/MS found forC9H9FN2 as (M+H)⁺ 165.2

EXAMPLE 1.33-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-methyl-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

This compound was obtained by taking in reaction step 2 the reactionpartner 3-methyl-7-amino-indole. Upon purification via HPLC the compoundhad been characterized:

¹H-NMR (400 MHz; DMSO-d₆, 100° C.): 10.78 (1H, s); 10.14 (1H, s); 7.34(1H, d); 7.23 (1H, d); 7.00 (1H, s), 6.96 (1H, t); 3.66 (1H, m); 2.95(1H, m); 2.27 (3H, s); 1.90-1.55 (8H, m); UPLC/MS found for C19H24N8O as(M+H)⁺ 381.1; UPLC retention time 0.63 min.

EXAMPLE 1.43-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

This compound was obtained by taking in reaction step 2 the reactionpartner 4-amino-indole. Upon purification via HPLC the compound had beencharacterized:

¹H-NMR (400 MHz; CD₃OD, 25° C.): 7.58 (1H, d); 7.45 (1H, d); 7.43 (1H,d); 7.23 (1H, t); 6.63 (1H, d); 4.40 (1H, m); 3.70 (1H, m); 2.00-1.55(8H, m); UPLC/MS found for C18H22N8O as (M+H)⁺ 367.0; UPLC retentiontime 0.52 min.

EXAMPLE 2.13-((1R,2S)-2-Amino-cyclohexylamino)-5-(1-methyl-1H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

Step 1: At 0° C. compound 8 (283 mg) was added to a solution of 1 (300mg) in NMP (2 mL) and the mixture was stirred for 10 min. Stirring wascontinued for 45 min at 25° C. Methanol (3 mL) was added, theprecipitate collected and dried to give compound 9 (389 mg) as a yellowsolid. UPLC/MS found for C15H16N6O2S as (M+H)⁺ 345.1; UPLC retentiontime 0.99 min.

Step 2: A mixture of 9 (362 mg) and NH₃ (5 mL of a 7 molar solution inmethanol) was stirred at 45° C. for 45 min. The precipitate wascollected and dried to give compound 10 (329 mg). UPLC/MS found forC13H13N7OS as (M+H)⁺ 316.0; UPLC retention time 0.86 min.

Step 3: At 0° C. MCPBA (448 mg) was added to a solution of 10 (315 mg)in DMF (5 mL) and the mixture stirred for 45 min. DMF (5 ml) was addedin portions while stirring was continued for 1.5 h at 45° C. NEt₃ (0.697mL) and 6 (236 mg) were added and the mixture stirred for 20 h at 25° C.The mixture was added to water, the precipitate collected and dried togive 11 (409 mg) as an orange solid. UPLC/MS found for C23H31N9O3 as(M+H)⁺ 482.1; UPLC retention time 0.96 min.

Step 4: A mixture of 11 (409 mg), CH₂Cl₂ (5 mL), TFA (1.0 mL) and water(0.01 mL) was stirred at 25° C. for 1 h. The solvents were removed andthe residue purified by HPLC. The TFA salt of Example 2.1 was passedthrough an Isolute SCX-2 column to yield the free base of Example 2.1(37 mg) as a yellow solid. ¹H-NMR (400 MHz; DMSO-d₆, 100° C.): 11.84(1H, s); 8.02 (1H, d), 7.97 (1H, s); 7.38 (1H, t), 7.33 (1H, d); 4.05(3H, s); 3.95 (1H, m); 3.15 (1H, m); 1.75-1.25 (8H, m); UPLC/MS foundfor C18H23N9O as (M+H)⁺ 382.1; UPLC retention time 0.56 min.

Examples 2.2-2.6 were prepared following procedures similar to thosedescribed for Example 2.1.

EXAMPLE 2.23-((1R,2S)-2-Amino-cyclohexylamino)-5-(2-methyl-2H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

In the synthesis of example 2.2, the reaction partner 8, i.e.1-methyl-4-amino-1H-indazol, was replaced by2-methyl-4-amino-2H-indazol. Upon purification via HPLC, the compoundwas characterized:

¹H-NMR (400 MHz; DMSO-d₆, 100° C.): 11.57 (1H, s); 8.18 (1H, s), 7.81(1H, d); 7.31 (1H, d), 7.19 (1H, t); 4.18 (3H, s); 3.92 (1H, m); 3.13(1H, m); 1.75-1.30 (8H, m); UPLC/MS found for C18H23N9O as (M+H)⁺ 382.1;UPLC retention time 0.52 min.

EXAMPLE 2.33-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-chloro-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

In the synthesis of example 2.3, the reaction partner 8 in the abovescheme, i.e. 1-methyl-4-amino-1H-indazol, was replaced by3-chloro-7-amino-1H-indole. Upon purification via HPLC, the compound wascharacterized:

¹H-NMR (400 MHz; CD₃OD, 25° C.): 7.50 (1H, d); 7.28 (1H, s), 7.27 (1H,d); 7.25 (1H, t); 3.50 (1H, m); 2.82 (1H, m); 1.70-1.15 (8H, m); UPLC/MSfound for C18H21ClN8O as (M+H)⁺ 401.0; UPLC retention time 0.67 min.

EXAMPLE 2.43-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-cyano-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

In the synthesis of example 2.4, the reaction partner 8 in the abovescheme, i.e. 1-methyl-4-amino-1H-indazol, was replaced by3-cyano-7-amino-1H-indole. Upon purification via HPLC, the compound wascharacterized:

¹H-NMR (400 MHz; CD₃OD, 25° C.): 7.99 (1H, s); 7.62 (1H, m), 7.31 (2H,m); 3.40 (1H, m); 2.78 (1H, m); 1.70-1.10 (8H, m); UPLC/MS found forC19H21N9O as (M+H)⁺ 392.0; UPLC retention time 0.58 min.

EXAMPLE 2.53-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

In the synthesis of example 2.5, the reaction partner 8 in the abovescheme, i.e. 1-methyl-4-amino-1H-indazol, was replaced by4-amino-1H-indazole. Upon purification via HPLC, the compound wascharacterized:

¹H-NMR (400 MHz; DMSO-d₆, 100° C.): 11.82 (1H, s); 8.02 (1H, s), 7.96(1H, d); 7.31 (2H, m), 7.33 (1H, d); 4.01 (1H, m); 3.24 (1H, m);1.75-1.30 (8H, m); UPLC/MS found for C17H21N9O as (M+H)⁺ 368.1; UPLCretention time 0.50 min.

EXAMPLE 2.63-((1R,2S)-2-Amino-cyclohexylamino)-5-(5-fluoro-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide

In the synthesis of example 2.6, the reaction partner 8 in the abovescheme, i.e. 1-methyl-4-amino-1H-indazol, was replaced by5-fluoro-7-amino-1H-indole. Upon purification via HPLC, the compound wascharacterized:

¹H-NMR (400 MHz; CD₃OD, 25° C.): 7.32 (1H, d); 7.25 (1H, m), 7.18 (1H,m); 6.50 (1H, d); 3.67 (1H, m); 2.93 (1H, m); 1.70-1.25 (8H, m); UPLC/MSfound for C18H21FN8O as (M+H)⁺ 385.1; UPLC retention time 0.61 min.

Preparation of 5-fluoro-7-amino-indole

A mixture of 7-Bromo-5-fluoro-indole (1 g), Cu (0.31 g), CuBr (0.64 g)and NH₃ (30 mL of a 33% aqueous solution) was heated in an autoclave for1.5 h at 155° C. The mixture was diluted with water and extracted withethyl acetate. The organic phase was dried and the solvent removed togive 5-fluoro-7-amino-indole (0.67 g) as an oil which was used withoutfurther purification. UPLC/MS found for C8H7FN2 as (M+H)⁺ 151.0.

EXAMPLE 3.15-((1R,2S)-2-Amino-cyclohexylamino)-3-(1-methyl-1H-indol-4-ylamino)-pyrazine-2-carboxylicacid amide

Step 1: At 0° C. a solution of 12 (2.59 g) and NEt₃ (1.744 ml) in DMF(20 ml), was added to a solution of 6 (2.95 g) in DMF (5 ml) and stirredfor 16 h at 25° C. The mixture was diluted with ethyl acetate (70 ml)and washed with water (50 ml). The aqueous phase was extracted withethyl acetate (30 ml), the combined organic phases washed with brine,dried over Na₂SO₄ and the solvent evaporated. Chromatography on silica(gradient cyclohexane/ethyl acetate) gave 13 (950 mg) as a yellow solid.UPLC/MS found for C17H25ClN4O4 as (M+1)⁺ 385.0, UPLC retention time 1.03min.

Step 2: To a solution of 13 (300 mg) in dioxan (2 ml) was added underargon at 25° C. 14 (171 mg), K₂CO₃ (1077 mg), Pd(OAc)₂ (1.75 mg) andXantphos (9.02 mg). The mixture was heated at 90° C. for 16 h. Themixture was diluted with ethyl acetate (30 ml) and washed with 0.1 N HCl(30 ml). The aqueous phase was extracted with Ethyl acetate (20 ml), thecombined organic phases washed with bicarbonate solution and brine. Themixture was dried over Na₂SO₄ and the solvent removed. Chromatography onsilica (gradient cyclohexane/ethyl acetate) gave 15 (242 mg, 62.8%).UPLC/MS found for C26H34N6O4 as (M+1)⁺ 495.1; UPLC retention time 1.29min.

Step 3: To a solution of 15 (242 mg, 0.489 mmol) in dioxan (1 ml) wasadded LiOH (82 mg) and water (0.5 ml). The mixture was stirred for 16 hat 25° C., diluted with ethyl acetate (30 ml), acidified with 0.1 N HCland extracted with ethyl acetate (20 ml). The organic phase was washedwith brine, dried over Na₂SO₄ and evaporated to dryness to give 16 (189mg, 80%). UPLC/MS found for C25H32N6O4 as (M+1)⁺=481.1; UPLC retentiontime 1.20 min.

Step 4: To a solution of 16 (189 mg) in DMF (2 ml) was added DIPEA(0.069 ml) followed by COMU (185 mg) and the resultant mixture stirredfor 5 min at 25° C. Ammonium hydroxide (0.337 ml of 25% aqueoussolution) and DIPEA (0.069 ml) were added and stirring continued for 30min. The mixture was diluted with ethyl acetate (20 ml), washed withbicarbonate solution (20 ml), dried and the solvent removed to give 17(154 mg). UPLC/MS found for C25H33N7O3 as (M+H)⁺ 480.1; UPLC retentiontime 1.17 min.

Step 5: To a solution of 17 (154 mg) in CH₂Cl₂ (10 ml) and MeOH (1 ml)was added TFA (0.495 ml) and the mixture stirred for 16 h at 25° C. Themixture was diluted with ethyl acetate (20 ml), washed with bicarbonatesolution (20 ml) and dried. Most of the solvent was removed, cyclohexanewas added and the precipitate collected. Example 3.1 was (103 mg) wasisolated as a yellow-brown solid. ¹H-NMR (400 MHz; DMSO-d₆, 100° C.):11.85 (1H, s); 8.17 (1H, m); 7.72 (1H, m); 7.47 (1H, s); 7.41 (1H, m);7.31 (1H, d); 7.24 (1H, m); 7.95 (2H, m); 6.51 (1H, d); 3.97 (1H, m);3.79 (3H, s); 3.02 (1H, m); 1.80-1.30 (8H, m); UPLC/MS found forC20H25N7O as (M+H)⁺=380.1; UPLC retention time 0.71 min.

EXAMPLE 4.15-((1R,2S)-2-Amino-cyclohexylamino)-3-(1H-indol-7-ylamino)-pyrazine-2-carboxylicacid amide

Step 1: At 0° C. 6 (739 mg) in DMF (2 ml) was added to a solution of 18(500 mg) and NEt₃ (0.401 ml, 2.87 mmol) in DMF (5 ml) and the mixturestirred for 16 h at 25° C. The mixture was diluted with ethyl acetate(50 ml) and washed with water (50 ml). The aqueous was extracted withethyl acetate (30 ml), the combined organic phases washed with brine,dried over Na₂SO₄ and the solvent removed. Chromatography on silica(gradient cyclohexane/ethyl acetate) gave 19 (905 mg) as a colorlesssolid. UPLC/MS found for C16H22ClN5O2 as (M+H)⁺ 352.0; UPLC retentiontime 1.13 min.

Step 2: To 19 (300 mg) in dioxan (2 ml) was added under argon 2 (135mg), K₂CO₃ (1178 mg), Pd(OAc)₂ (1.91 mg) and Xantphos (9.9 mg). Themixture was stirred for 16 h at 90° C. The mixture was diluted withethyl acetate (20 ml), washed with HCl (0.1 N; 30 ml). The aqueous phasewas extracted with ethyl acetate (20 ml), the combined organic phaseswashed with bicarbonate solution and brine, dried over Na₂SO₄ and thesolvent removed. Chromatography on silica (gradient cyclohexane/ethylacetate) gave 20 (368 mg). UPLC/MS found for C24H29N7O2 as (M+H)⁺ 448.1;UPLC retention time 1.19 min.

Step 3: To 20 (368 mg) in DMSO (2 ml) and EtOH (4 ml) was added at 0° C.NaOH (1.03 ml) and H₂O₂ (0.382 ml). After stirring for 2 h at 25° C. themixture was partitioned between water and Ethyl acetate (30 ml each).The organic phase was washed with bicarbonate solution and brine, driedover Na₂SO₄ and the solvent removed to give crude 21 (320 mg) which wasused without further purification in the next step. UPLC/MS found forC24H31N7O3 (M+H)⁺ 466.1; UPLC retention time 1.18 min.

Step 4: To 21 (320 mg) in CH₂Cl₂ (20 ml) and MeOH (4 ml) was added HCl(4N, 3.44 ml) and the mixture stirred for 16 h at 25° C. The mixture wasdiluted with CH₂Cl₂ (50 ml) and washed with bicarbonate solution andbrine, dried with Na₂SO₄ and the solvent removed. Chromatography using aKP-NH column (gradient MeOH/ethyl acetate gradient) gave Example 4.1 (74mg) as a yellow solid. ¹H-NMR (400 MHz; DMSO-d₆, 25° C.): 11.04 (1H, s);10.71 (1H, s); 7.67 (1H, m); 7.42 (1H, s); 7.32 (1H, d); 7.28 (1H, d);7.24 (1H, m); 7.22 (1H, m); 7.18 (1H, m); 6.93 (1H, t); 6.44 (1H, m);3.65 (1H, m); 2.87 (1H, m); 1.55-1.03 (8H, m); UPLC/MS found forC19H23N7O (M+H)⁺ 366.1; UPLC retention time 0.65 min.

Example 4.2 was prepared following procedures similar to those describedfor Example 4.1, i.e. in reaction step 2,7-amino-1H-indole was replacedby 3-methyl-7-amino-1H-indole.

EXAMPLE 4.25-((1R,2S)-2-Amino-cyclohexylamino)-3-(3-methyl-1H-indol-7-ylamino)-pyrazine-2-carboxylicacid amide

¹H-NMR (400 MHz; DMSO-d₆, 25° C.): 11.06 (1H, s); 10.35 (1H, s); 7.67(1H, m); 7.42 (1H, s); 7.33 (1H, d); 7.25 (1H, m); 7.24 (1H, d); 7.17(1H, m); 7.02 (1H, m); 6.92 (1H, t); 3.66 (1H, m); 2.88 (1H, m); 2.26(3H, s); 1.60-1.08 (8H, m); UPLC/MS found for C20H25N7O as (M+H)⁺=380.1;UPLC retention time 0.71 min.

Biopharmaceutical Part

The compounds of the invention in free form or in pharmaceuticallyacceptable salt form, exhibit valuable pharmacological properties asdescribed in the tests below, e.g. in vitro and in vivo tests, and aretherefore indicated for therapy.

Syk Enzyme Assay

A number of compounds of the present invention were assayed in a chipbased microfluidic mobilitiy shift assay. All assays were performed in384 well microtiter plates. Each assay plate contained 8-point serialdilutions for 40 test compounds, as well as four 8-point serialdilutions of staurosporine as reference compound, plus 16 high- and 16low controls. Liquid handling and incubation steps were done on a ThermoCatX workstation equipped with a Innovadyne Nanodrop Express. Betweenpipetting steps, tips were cleaned in wash cycles using wash buffer. Theassay plates were prepared by addition of 50 nl per well of compoundsolution in 90% DMSO. The kinase reactions were started by stepwiseaddition of 4.5 μl per well of peptide/ATP-solution (50 mM HEPES, pH7.5, 1 mM DTT, 0.02% Tween20, 0.02% BSA, 0.6% DMSO, 10 mMbeta-glycerophosphate, and 10 μM sodium orthovanadate, 1 mM MgCl₂, 3 mMMnCl₂, 4 μM ATP, 4 μM peptide (5-Fluo-Ahx-GAPDYENLQELNKK-Amid)(purchased from Biosyntan, Berlin, Germany) and 4.5 μl per well ofenzyme solution (50 mM HEPES, pH 7.5, 1 mM DTT, 0.02% Tween20, 0.02%BSA, 0.6% DMSO, 10 mM beta-glycerophosphate, and 10 μM sodiumorthovanadate, 1 mM MgCl₂, 3 mM MnCl₂, 4 nM Syk (Syk (2-635)(UniProtKB/Swiss-Prot: KSYK_HUMAN, P43405), produced in-house frominsect cells). Kinase reactions were incubated at 30° C. for 60 minutesand subsequently terminated by addition of 16 μl per well of stopsolution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% Caliper coating reagent, 10mM EDTA, and 0.015% Brij35). Plates with terminated kinase reactionswere transferred to the Caliper LC3000 workstations for reading.Phosphorylated and unphosphorylated peptides were separated using theCaliper microfluidic mobility shift technology. Briefly, samples fromterminated kinase reactions were applied to the chip. Analytes aretransported through the chip by constant buffer flow and the migrationof the substrate peptide is monitored by the fluorescence signal of itslabel. Phosphorylated peptide (product) and unphosphorylated peptide(substrate) are separated in an electric field by their charge/massratio. Kinase activities were calculated from the amounts of formedphospho-peptide. 1050 values were determined from percent inhibitionvalues at different compound concentrations by non-linear regressionanalysis.

Preparation of Compound Dilutions

Test compounds were dissolved in DMSO (10 mM) and transferred into 1.4mL flat bottom or V-shaped Matrix tubes carrying a unique 2D matrix. Thestock solutions were stored at +2° C. if not used immediately. For thetest procedure the vials were defrosted and identified by a scannerwhereby a working sheet was generated that guided the subsequent workingsteps.

Compound dilutions were made in 96 well plates. This format enabled theassay of maximally 40 individual test compounds at 8 concentrations(single points) including 4 reference compounds. The dilution protocolincluded the production of “pre-dilution plates”, “master plates” and“assay plates”.

Pre-Dilution Plates:

96 polypropylene well plates were used as pre-dilution plates. A totalof 4 pre-dilution plates were prepared including 10 test compounds eachon the plate positions A1-A10, one standard compound at A11 and one DMSOcontrol at A12. All dilution steps were done on a HamiltonSTAR robot.

Master Plates:

30 μL of individual compound dilutions including standard compound andcontrols of the 4 “pre-dilution plates” were transferred into a 384“master plate” including the following concentrations 1′810, 362, 72.5,54.6, 14.5, 2.9, 0.58 and 0.12 μM, respectively in 90% of DMSO.

Assay Plates:

Identical “assay plates” were then prepared by pipetting 50 mL each ofcompound dilutions of the “master plates” into 384-well “assay plates”by means of a HummingBird 384-channel dispenser. These plates were useddirectly for the assay which was performed in a total volume of 9.05 μL.This led to a final compound concentration of 10, 2.0, 0.4, 0.08, 0.016,0.0032, 0.00064 and 0.000128 μM and a final DMSO concentration of 0.5%in the assay.

In this assay, the compounds of the invention had IC₅₀ values providedinfra:

IC₅₀-Values

SYK IC₅₀ Example [uM] 1.1 0.023 1.2 0.0008 1.3 0.0035 1.4 0.001 2.10.012 2.2 0.0051 2.3 0.011 2.4 0.086 2.5 0.030 2.6 0.0046 3.1 0.0005 4.10.0027 4.2 0.001 [uM] means micromol per literInhibition of the hERG (Human Ether-a-Gogo-Related-Gene) Channel (ManualPatch Clamp Assay)

The hERG patch clamp assay was done according to standard proceduresused in Genetic Toxicology and Safety Pharmacology, based onrecommendations and descriptions of methods in the literature, andaccording to current guidelines (ICH S7B, The non clinical evaluation ofthe potential for delayed ventricular repolarization (QT intervalprolongation) by human pharmaceuticals, 2005). The purpose of the studyis to assess the effect of the test item ABC123 on tail current recordedfrom HEK293 cells stably transfected with hERG cDNA. The HEK293 cells,which have been stably transfected with hERG cDNA, are a modelconsidered to be suitable for this purpose (Zhou et al., 1998).Repolarisation of cardiac ventricular myocytes is mainly due to outwardpotassium currents. The most important current in humans is the delayedrectifier potassium current, I_(K), which has both rapidly and slowlyactivating components (I_(Kr) and I_(Ks)) (Sanguinetti and Jurkiewicz,1990). The human ether-a-gogo-related-gene (hERG) encodes the majorprotein underlying I_(Kr). Thus, inhibition of hERG potassium channelsmay lead to delayed cardiac repolarisation (Sanguinetti et al., 1995).Prolongation of cardiac repolarisation is a side effect that can beassociated with some drug therapies. This proarrhythmic alteration ischaracterised by a prolongation of the QT interval in the surfaceelectrocardiogram and is of particular concern because it may lead tothe development of polymorphic ventricular arrhythmias like torsade depointes (for review see: Vandenberg, Walker and Campbell, 2001).Compounds which inhibit the hERG current in vitro have been shown topossess the potential of prolonging the cardiac action potential andhence prolong the QT interval in man (Ficker et al., 1998; Kiehn et al.,1996; Mohammad et al., 1997).

HERG HEK (HEK293 cells stably transfected with hERG cDNA) obtained fromthe University of Wisconsin were used. For the experiments the cellswere plated onto sterile Thermanox plastic coverslips (Nalge NuncInternational) in 6-well plates. The dishes were stored in a humidified,gassed incubator. The coverslips with cells were transferred to therecording chamber and continuously superfused (at approximately 1-2ml/min) with vehicle. The temperature of the vehicle in the bath chamberwas regulated by temperature controllers to 35° C.±2.0° C. hERG currentswere measured in the whole-cell patch-clamp configuration. Once a stablepatch clamp configuration was achieved, recording commenced involtage-clamp mode, with the cell initially clamped at −75 mV. hERGcurrent was observed and recorded if a stable hERG tail current responsecould be induced. Afterwards the test item was perfused through thebath; fluid exchange took approximately 1-2 min to achieve the nominaltest item concentration. The hERG HEK293 cells were treatedapproximately 9 min with the test item. The following voltage protocolwas applied to induce hERG currents: The step from −75 mV to +10 mVactivates an outward current (i.e. current flows out of the cell) andthe step from +10 mV to −40 mV produces the tail current (the tailcurrent represents the time taken for the current to turn off). Thevoltage was held at +10 mV for 500 ms and at −40 mV for 500 ms, giving atotal pulse length of 1 s. To determine the test item effect on the hERGcurrent the voltage protocol was applied at a frequency of 0.1 Hz. Theleak current was recorded and subtracted by a P/3n pulse between thevoltage pulses (0.1 Hz).

References Recited in the Above hERG-Experiment:

-   ICH S7B: The non clinical evaluation of the potential for delayed    ventricular repolarization (QT interval prolongation) by human    pharmaceuticals, 2005.-   [Ficker E, Jarolimek W, Kiehn J, et al. (1998)]. Molecular    determinants of dofetilide block of HERG K+ channels. Circ Res;    82(3): 386-395.-   [Kiehn J, Lacerda A E, Wible B, Brown A M (1996)]. Molecular    physiology and pharmacology of HERG. Single-channel currents and    block by dofetilide. Circulation; 94(10): 2572-2579.-   [Mohammad S, Zhou Z, Gong Q, January C T (1997)]. Blockage of the    HERG human cardiac K+ channel by the gastrointestinal prokinetic    agent cisapride. Am J Physiol; 273 (5 Pt 2): H2534-H2538.-   [Sanguinetti M C, Jiang C, Curran M E, Keating M T (1995)]. A    mechanistic link between an inherited and an acquired cardiac    arrhythmia: HERG encodes the IKr potassium channel. Cell; 81(2):    299-307.-   [Sanguinetti M C and Jurkiewicz N K (1990)]. Two components of    cardiac delayed rectifier K+ current. Differential sensitivity to    block by class III antiarrhythmic agents. J Gen Physiol; 96(1):    195-215.-   [Trudeau M, Warmke J W, Ganetzky B, Robertson G A (1995)]. HERG, a    human inward rectifier In the voltage-gated potassium channel    family. Science; 269: 92-95.-   [Vandenberg J I, Walker B D, Campbell T J (2001)]. HERG K+ channels:    friend and foe. Trends Pharmacol Sci; 22(5): 240-246.-   [Zhou Z, Gong Q, Ye B, Fan Z, Makielski J C, Robertson G A, January    C T (1998)]. Properties of HERG channels stably expressed in HEK 293    cells studied at physiological temperature. Biophys J; 74(1):    230-241.

In this assay, the compounds of the invention have %-inhibition valuesprovided infra:

%-Inhibition of hERG Channel Activity

Ex. 1.1 Ex. 1.3 not tested at 3 uM 24 ± 3% at 3 uM −5 ± 4% at 10 uM 37 ±6% at 10 uM 12 ± 6% at 30 uM 74 ± 6% at 30 uM uM means micromol perliter

In Vitro Cellular Assays: B Cell Receptor:

Anti IgM-induced phosphorylation of BLNK (BLNK=B cell linker (SLP65=SH2domain containing leukocyte protein of 65 kDa)) in Ramos B cells:

Ramos B cells in a volume of 25 μl were incubated with 25 μl of thecompound solution at 2-fold the desired final concentration for 30 min.at 37° C. Then 50 μL anti IgM was added, mixed and incubated for 15 min.at 37° C. In each experiment 8-fold serial dilutions of compounds weretested. The stimulation was stopped by addition of 100 μL/well of PFA(para formaldehyde) I PBS (phosphate buffered saline) (final conc. 2%PFA) for fixation and incubated for 15 min. at 37° C., then centrifugedat 1300 rpm for 3 min and permeabilized by resuspending the cell pelletin 100 μL methanol 90% and further incubated for 30 min at 4° C. Thecells were then washed and phosphoproteins were detected by flowcytometry using fluorescently labeled anti-BLNK (pY84) (BD Biosciences).

Compounds of the inventions had the following efficacy in this assay:

Anti IgM induced phosphorylation of Example No BLNK in Ramos B cells;IC50 in nM 1.1 106 1.2 63 1.3 72 1.4 14 2.1 121 2.2 58 2.3 393 2.4 8902.5 106 2.6 37 3.1 25 4.1 28 4.2 36

Fc Gamma Receptor Assays: FcR Stimulation-Induced SLP-76 Phosphorylationin Human Whole Blood Monocytes

Heparin—anticoagulated human whole blood (90 μL/well) was mixed withserial dilutions of compounds to be tested (10 μL per well) for 30 minat 37° C. followed by stimulation with anti CD32 antibody clone 6C4 for5 min at 37° C. After lysis of erythrocytes and washings, the cellpellet was permeabilized with ice-cold methanol 90%. The permeabilizedcells were washed and stained with anti CD14 (eBioscience) to detectmonocytes and anti P-SLP76 (pY128) (BD Biosciences) and quantified byflow cytometry.

Compounds of the inventions had the following efficacy in this assay:

Fc Recepor stimulation induced SLP-76 (SH2 domain containing leukocyteprotein of 76 kDa) phosphorylation in Example No. human whole bloodmonocytes, IC50 in nM 1.1 378 1.2 491 1.3 447 1.4 177 2.1 509 2.2 3942.5 671 2.6 562 4.1 311 4.2 596

B-Cell Lymphoma Cell Proliferation:

Cell proliferation was determined using the WST-1 assay (Roche,Mannheim, Germany), which measures the metabolic activity of the cells.Briefly, 5×10⁵ TMD-8, OCI-Ly3, and OCI-Ly10 cells/well and 10×10⁵ HBL-1cells/well were seeded in triplicate in 96-well plates and wereincubated with various concentrations of compounds to be tested for 3days. The cell proliferation reagent WST-1 (10 μl/well) was added to thecells for 1-2 hours depending on the cell type which were cultured in200 μl of medium. The absorbance was then measured with an enzyme-linkedimmunosorbent assay plate reader at a wavelength of 450 nm. Theconcentrations required to inhibit growth by 50% (GI50) was assessed.

The following efficacy was determined for example 1.1:

Example 1.1 Cell lines TMD-8 OCI-Ly3 OCI-Ly10 HBL-1 GI50 (nM) 281 Noinhibition 25 105 Days of incubation 4 4 3 4

Utility Section

The compounds of the invention are therefore useful in the prevention ortreatment of disorders or diseases where for example SYK inhibitionplays a role, e.g. diseases or disorders mediated by, B lymphocytes,myeloid cells, neutrophils, mast cells, platelets basophils and/oreosinophils e.g. acute or chronic rejection of organ or tissue allo- orxenografts, atheriosclerosis, vascular occlusion due to vacular injurysuch as angioplasty, restenosis, hypertension, heart failure, chronicobstructive pulmonary disease, CNS disease such as Alzheimer disease oramyotrophic lateral sclerosis, cancer, infectious disease such as AIDS,septic shock or adult respiratory distress syndrome,ischemia/reperfusion injury e.g. myocardial infarction, stroke, gutischemia, renal failure or hermorrhage shock, or traumatic shock, gout,urticaria such as acute or chronic idiopathic or allergic urticaria,autoimmune hemolytic anemia, nephropathies such as IgA nephropathy,Sjögren's syndrome, cryoglobulinemias such as mixed cryoglobulinemiatype I, II or III, inflammatory bowel diseases such as Crohn's diseaseor ulcerative colitis atherosclerosis, and osteoporosis.

In another embodiment compounds of the invention may in particular befor use in the prevention and/or treatment of urticaria, such as acuteor chronic idiopathic or allergic urticaria.

The agent of the invention are also useful in the treatment and/orprevention of acute or chronic inflammatory diseases or disorders orautoimmune diseases e.g. rheumatoid arthritis, osteoarthritis, systemiclupus erythematosus, Hashimoto's thyroidis, multiple sclerosis,myasthenia gravis, diabetes mellitus (type I and II) and the disordersassociated therewith, vascular manifestations of autoimmune andinflammatory diseases (vasculitides), respiratory diseases such asasthma or inflammatory liver injury, inflammatory glomerular injury,cutaneous manifestations of immunologically-mediated disorders orillnesses, inflammatory and hyperproliferative skin diseases (such aspsoriasis, atopic dermatitis, allergic contact dermatitis, irritantcontact dermatitis and further eczematous dermatitises, seborrhoeicdermatitis), inflammatory eye diseases, e.g. Sjoegren's syndrome,keratoconjunctivitis or uveitis, inflammatory bowel disease, Crohn'sdisease or ulcerative colitis, immune and/or idiopathicthrombocytopenia, allergies, wound healing, and Graft vs host disease.

In another embodiment compounds of the invention may in particular befor use in the prevention and/or treatment of acute or chronicinflammatory diseases or disorders or autoimmune diseases e.g.rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus,Hashimoto's thyroidis, multiple sclerosis.

In another embodiment compounds of the invention may in particular befor use in the prevention and/or treatment of immune and/or idiopathicthrombocytopenia.

Compounds of the invention are also useful in the prevention ortreatment of tumors, for example brain and other central nervous systemtumors (eg. tumors of the meninges, brain, spinal cord, cranial nervesand other parts of central nervous system, e.g. glioblastomas or medullablastomas); head and/or neck cancer; breast tumors; circulatory systemtumors (e.g. heart, mediastinum and pleura, and other intrathoracicorgans, vascular tumors and tumor-associated vascular tissue); excretorysystem tumors (e.g. kidney, renal pelvis, ureter, bladder, other andunspecified urinary organs); gastrointestinal tract tumors (e.g.oesophagus, stomach, small intestine, colon, colorectal, rectosigmoidjunction, rectum, anus and anal canal), tumors involving the liver andintrahepatic bile ducts, gall bladder, other and unspecified parts ofbiliary tract, pancreas, other and digestive organs); head and neck;oral cavity (lip, tongue, gum, floor of mouth, palate, and other partsof mouth, parotid gland, and other parts of the salivary glands, tonsil,oropharynx, nasopharynx, pyriform sinus, hypopharynx, and other sites inthe lip, oral cavity and pharynx); reproductive system tumors (e.g.vulva, vagina, Cervix uteri, Corpus uteri, uterus, ovary, and othersites associated with female genital organs, placenta, penis, prostate,testis, and other sites associated with male genital organs);respiratory tract tumors (e.g. nasal cavity and middle ear, accessorysinuses, larynx, trachea, bronchus and lung, e.g. small cell lung canceror non-small cell lung cancer); skeletal system tumors (e.g. bone andarticular cartilage of limbs, bone articular cartilage and other sites);skin tumors (e.g. malignant melanoma of the skin, non-melanoma skincancer, basal cell carcinoma of skin, squamous cell carcinoma of skin,mesothelioma, Kaposi's sarcoma); and tumors involving other tissuesincluing peripheral nerves and autonomic nervous system, connective andsoft tissue, retroperitoneum and peritoneum, eye and adnexa, thyroid,adrenal gland and other endocrine glands and related structures,secondary and unspecified malignant neoplasm of lymph nodes, secondarymalignant neoplasm of respiratory and digestive systems and secondarymalignant neoplasm of other sites, tumors of blood and lymphatic system(e.g. Hodgkin's disease, Non-Hodgkin's lymphoma, Burkitt's lymphoma,AIDS-related lymphomas, malignant immunoproliferative diseases, multiplemyeloma and malignant plasma cell neoplasms, lymphoid leukemia, acute orchronic myeloid leukemia, acute or chronic lymphocytic leukemia,monocytic leukemia, other leukemias of specified cell type e.g. diffuselarge B cell lymphomas, leukemia of unspecified cell type, other andunspecified malignant neoplasms of lymphoid, haematopoietic and relatedtissues, for example diffuse large cell lymphoma, T-cell lymphoma orcutaneous T-cell lymphoma). Myeloid cancer includes e.g. acute orchronic myeloid leukaemia.

In another embodiment compounds of the invention may in particular befor use in the prevention and/or treatment of leukemia of specified celltype e.g. diffuse large B cell lymphoma.

Where hereinbefore and subsequently a tumor, a tumor disease, acarcinoma or a cancer is mentioned, also metastasis in the originalorgan or tissue and/or in any other location are implied alternativelyor in addition, whatever the location of the tumor and/or metastasis is.

Dosage(s), Administration(s):

For the above uses the required dosage will of course vary depending onthe mode of administration, the particular condition to be treated andthe effect desired. In general, satisfactory results are indicated to beobtained systemically at daily dosages of from about 0.02 to 25 mg/kgper body weight. An indicated daily dosage in the larger mammal, e.g.humans, may be typically in the range from about 0.2 mg to about 2 g,conveniently administered, for example, in divided doses up to fourtimes a day or in retard form. Suitable unit dosage forms for oraladministration may typically comprise from ca.0.1 to 500 mg activeingredient.

The compounds of the invention may be administered by any conventionalroute, in particular parenterally, for example in the form of injectablesolutions or suspensions, enterally, e.g. orally, for example in theform of tablets or capsules, topically, e.g. in the form of lotions,gels, ointments or creams, or in a nasal or a suppository form. Topicaladministration may for example be to the skin. A further form of topicaladministration may be to the eye. Pharmaceutical compositions comprisinga compound of the invention in association with at least onepharmaceutical acceptable carrier or diluent may be manufactured inconventional manner by mixing with a pharmaceutically acceptable carrieror diluent.

The compounds of the invention may be administered in free form or inpharmaceutically acceptable salt form, e.g. as indicated above. Suchsalts may be prepared in conventional manner and may typically exhibitthe same order of activity as the free compounds.

Combinations:

Compounds of the invention may be administered as the sole activeingredient or together with other drugs useful against neoplasticdiseases, inflammatory disorders or in immunomodulating regimens. Forexample, the compounds of the invention may be used in combination withan active agent effective in various diseases as described above, e.g.with cyclosporins, rapamycins or ascomycins, or their immunosuppressiveanalogs or derivatives, e.g. cyclosporin A, cyclosporin G, Isa tx247,FK-506, sirolimus or everolimus; CCl-779, ABT578, AP23573,corticosteroids e.g. prednisone; cyclophosphamide; azathioprine;methotrexate; gold salts, sulfasalazine, antimalarials; leflunomide;mizoribine; mycophenolic acid; mycophenolate mofetil;15-deoxyspergualine; an S1P receptor modulator having acceleratinglymphocyte homing activity, e.g FTY720 or an analogue thereof,immuno-suppressive monoclonal antibodies, e.g. monoclonal antibodies toleukocyte receptors, e.g. MHC, CD2, CD3, CD4, CD7, CD25, CD28, CD40,CD45, CD58, CD80, CD86, CD152, CD137, CD154, ICOS, LFA-1, VLA-4 or theirligands; or other immunomodulatory compounds, e.g. CTLA4Ig;

Jak inhibitors, anti IL-17, IL-1, anti TNF, TNF receptor blocker, antiCD20, anti CD19, PI3 kinase inhibitors, or Btk inhibitors.

A compound of the invention may also be used to advantage in combinationwith other antiproliferative agents. Such antiproliferative agentsinclude, but are not limited to aromatase inhibitors, antiestrogens,topoisomerase I inhibitors, topoisomerase II inhibitors, microtubuleactive agents, alkylating agents, histone deacetylase inhibitors,farnesyl transferase inhibitors, COX-2 inhibitors, MMP inhibitors, mTORinhibitors, antineoplastic antimetabolites, platin compounds, compoundsdecreasing the protein kinase activity and further anti-angiogeniccompounds, gonadorelin agonists, anti-androgens, bengamides,bisphosphonates, antiproliferative antibodies and temozolomide(TEMODAL®).

The term “aromatase inhibitors” as used herein relates to compoundswhich inhibit the estrogen production, i.e. the conversion of thesubstrates androstenedione and testo-sterone to estrone and estradiol,respectively. The term includes, but is not limited to steroids,especially exemestane and formestane and, in particular, non-steroids,especially aminoglutethimide, vorozole, fadrozole, anastrozole and, veryespecially, letrozole. A combination of the invention comprising anantineoplastic agent which is an aromatase inhibitor may particularly beuseful for the treatment of hormone receptor positive breast tumors.

The term “antiestrogens” as used herein relates to compounds whichantagonize the effect of estrogens at the estrogen receptor level. Theterm includes, but is not limited to tamoxifen, fulvestrant, raloxifeneand raloxifene hydrochloride.

The term “topoisomerase I inhibitors” as used herein includes, but isnot limited to topotecan, irinotecan, 9-nitrocamptothecin and themacromolecular camptothecin conjugate PNU-166148 (compound A1 inWO99/17804).

The term “topoisomerase II inhibitors” as used herein includes, but isnot limited to the antracyclines doxorubicin (including liposomalformulation, e.g. CAELYXT™), epirubicin, idarubicin and nemorubicin, theanthraquinones mitoxantrone and losoxantrone, and the podophillotoxinesetoposide and teniposide.

The term “microtubule active agents” relates to microtubule stabilizingand microtubule destabilizing agents including, but not limited to thetaxanes paclitaxel and docetaxel, the vinca alkaloids, e.g.,vinblastine, especially vinblastine sulfate, vincristine especiallyvincristine sulfate, and vinorelbine, discodermolide and epothilones,such as epothilone B and D.

The term “alkylating agents” as used herein includes, but is not limitedto cyclophos-phamide, ifosfamide and melphalan.

The term “histone deacetylase inhibitors” relates to compounds whichinhibit the histone deacetylase and which possess antiproliferativeactivity.

The term “farnesyl transferase inhibitors” relates to compounds whichinhibit the farnesyl transferase and which possess antiproliferativeactivity.

The term “COX-2 inhibitors” relates to compounds which inhibit thecyclooxygenase type 2 enyzme (COX-2) and which possess antiproliferativeactivity such as celecoxib (Celebrex®), rofecoxib (Vioxx®) andlumiracoxib (COX189).

The term “MMP inhibitors” relates to compounds which inhibit the matrixmetalloproteinase (MMP) and which possess antiproliferative activity.

The term “antineoplastic antimetabolites” includes, but is not limitedto 5-fluorouracil, tegafur, capecitabine, cladribine, cytarabine,fludarabine phosphate, fluorouridine, gemcitabine, 6-mercaptopurine,hydroxyurea, methotrexate, edatrexate and salts of such compounds, andfurthermore ZD 1694 (RALTITREXED™), LY231514 (ALIMTA™), LY264618(LOMOTREXOL™) and OGT719.

The term “platin compounds” as used herein includes, but is not limitedto carboplatin, cis-platin and oxaliplatin.

The term “compounds decreasing the protein kinase activity and furtheranti-angiogenic compounds” as used herein includes, but is not limitedto compounds which decrease the activity of e.g. the VascularEndothelial Growth Factor (VEGF), the Epidermal Growth Factor (EGF),c-Src, protein kinase C, Platelet-derived Growth Factor (PDGF), Bcr-Abltyrosine kinase, c-kit, Flt-3 and Insulin-like Growth Factor I Receptor(IGF-IR) and Cyclin-dependent kinases (CDKs), and anti-angiogeniccompounds having another mechanism of action than decreasing the proteinkinase activity.

The term “gonadorelin agonist” as used herein includes, but is notlimited to abarelix, goserelin and goserelin acetate. Goserelin isdisclosed in U.S. Pat. No. 4,100,274.

The term “anti-androgens” as used herein includes, but is not limited tobicalutamide (CASODEXT™), which can be formulated, e.g. as disclosed inU.S. Pat. No. 4,636,505.

The term “bengamides” relates to bengamides and derivatives thereofhaving aniproliferative properties.

The term “bisphosphonates” as used herein includes, but is not limitedto etridonic acid, clodronic acid, tiludronic acid, pamidronic acid,alendronic acid, ibandronic acid, risedronic acid and zoledronic acid.

The term “antiproliferative antibodies” as used herein includes, but isnot limited to trastuzumab (Herceptin™), Trastuzumab-DM1, erlotinib(Tarceva™), bevacizumab (Avastin™), rituximab (Rituxan®), PRO64553(anti-CD40) and 2C4 Antibody.

What is claimed is:
 1. A compound of the formula (I) or apharmaceutically acceptable salt thereof,

wherein X1 is CH or N; Y1, Y2 and Y3 are depending on the position ofthe double bond independently of each other CH, NH or N, and the bentbond indicates aromaticity of the ring system; R1 is H, alkyl, CN, orHal; and R2 is H, alkyl, or Hal; and

wherein the above structural part (L) in a compound of formula (I) is afully aromatic bicyclic system containing at least 1 nitrogen atomrepresented by anyone of the members Y1, Y2 and Y3.
 2. A compound ofclaim 1 or a pharmaceutically acceptable salt thereof, wherein X1 is N;Y1 is NH, Y2 is N and Y3 is CH; or Y1 is CH, Y2 is N and Y3 is NH; R1 isH, C₁₋₄alkyl, CN, or Hal; and R2 is H, C₁₋₄alkyl or Hal.
 3. A compoundof claim 1 or a pharmaceutically acceptable salt thereof, wherein X1 isN; Y1 is NH; Y2 and Y3 are CH; R1 is H, C₁₋₄alkyl, CN, or Hal; and R2 isH, C₁₋₄alkyl or Hal.
 4. A compound according to claim 1 which is acompound of formula (II) or a pharmaceutically acceptable salt thereof,wherein

X1 is CH or N; R1 is H, C₁₋₄alkyl, CN, or Hal; and R2 is H, C₁₋₄alkyl orHal.
 5. A compound in accordance to claim 4 or a pharmaceuticallyacceptable salt thereof, wherein X1 is CH; R1 is H, C₁₋₄alkyl, CN, orHal; and R2 is H, C₁₋₄alkyl or Hal.
 6. A compound in accordance to claim4 or a pharmaceutically acceptable salt thereof, wherein X1 is CH; R1 isH or methyl; and R2 is H or fluoro.
 7. A compound of claim 4 or apharmaceutically acceptable salt thereof, wherein X1 is N; R1 is H,C₁₋₄alkyl, CN, or Hal; and R2 is H, C₁₋₄alkyl or Hal.
 8. A compound ofclaim 4 or a pharmaceutically acceptable salt thereof, wherein X1 is N;R1 is H or methyl; and R2 is H or fluoro.
 9. A compound of claim 4 or apharmaceutically acceptable salt thereof, wherein X1 is N, and whereinR1 and R2 are both hydrogen.
 10. A compound according to claim 1, whichis a compound of formula (III) or a pharmaceutically acceptable saltthereof, wherein

R is H or C₁₋₄alkyl; R1 is H, C₁₋₄alkyl, CN, or Hal; and R2 is H,C₁₋₄alkyl or Hal.
 11. A compound of claim 10 or a pharmaceuticallyacceptable salt thereof, wherein R is methyl; R1 is H or methyl; and R2is H, methyl or fluoro.
 12. A compound in accordance to claim 1, whichis a compound of formula (IV) or a pharmaceutically acceptable saltthereof, wherein

R1 is H, C₁₋₄alkyl, CN, or Hal; and R2 is H, C₁₋₄alkyl or Hal.
 13. Acompound of claim 12 or a pharmaceutically acceptable salt thereof,wherein R1 is H or methyl; and R2 is H, methyl or fluoro.
 14. A compoundof claim 12 or a pharmaceutically acceptable salt thereof, wherein R1 isH or methyl; and R2 is H.
 15. A compound in accordance to claim 1 or apharmaceutically acceptable salt thereof, wherein said compound isselected from:3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(5-fluoro-3-methyl-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-methyl-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1-methyl-1H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(2-methyl-2H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-chloro-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(3-cyano-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(1H-indazol-4-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;3-((1R,2S)-2-Amino-cyclohexylamino)-5-(5-fluoro-1H-indol-7-ylamino)-[1,2,4]triazine-6-carboxylicacid amide;5-((1R,2S)-2-Amino-cyclohexylamino)-3-(1-methyl-1H-indol-4-ylamino)-pyrazine-2-carboxylicacid amide;5-((1R,2S)-2-Amino-cyclohexylamino)-3-(1H-indol-7-ylamino)-pyrazine-2-carboxylicacid amide; and5-((1R,2S)-2-Amino-cyclohexylamino)-3-(3-methyl-1H-indol-7-ylamino)-pyrazine-2-carboxylicacid amide.
 16. A pharmaceutical composition comprising atherapeutically effective amount of a compound according to claim 1 andone or more pharmaceutically acceptable carriers.
 17. A combinationcomprising a therapeutically effective amount of a compound according toclaim 1 and one or more therapeutically active co-agents.
 18. A methodof modulating SYK activity in a subject, wherein the method comprisesadministering to the subject a therapeutically effective amount of thecompound according to claim
 1. 19-20. (canceled)